Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 156 The United Laboratories International Holdings Limited Annual Report 2019 Name of subsidiary Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2019 2018 內蒙古聯邦動保藥品有限公司 (Note c) The PRC RMB35,200,000 100% 100% Manufacturing and sale of pharmaceutical intermediate products in the PRC 聯邦制藥（中國）有限公司 (Note b) The PRC RMB160,080,000 100% 100% Investment holding in the PRC 珠海聯邦金龍行銷策劃有限公司 (Note c) The PRC RMB50,000,000 100% 100% Providing management services in the PRC 成都樂邦生物醫藥科技有限公司 (Note c and e) The PRC RMB1,000,000 100% N/A Investment holding in the PRC 成都智匯城有限公司 (Note c and e) The PRC RMB10,000,000 100% N/A Investment holding in the PRC 聯邦製藥（中山）有限公司 (Note c) The PRC RMB50,000,000 100% 100% Manufacturing and sale of pharmaceutical products and food production in the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. (e) A company established in the PRC during the year ended 31 December 2019. (f) 珠海聯邦制藥股份有限公司 issued unsecured corporate bonds which are listed on the Shanghai Stock Exchange as at 31 December 2019 and 2018. Details are set out in Note 31. (g) The company has been disposed to a third party during the year ended 31 December 2019. As at 31 December 2019 and 2018, none of the subsidiaries had issued any debt securities except for 珠海 聯邦制藥股份有限公司 which has issued RMB1,100,000,000 of bonds, in which the Group has no interest. 46. LIST OF SUBSIDIARIES (Continued)